Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
AdAlta Ltd. ( (AU:1AD) ) has issued an update.
AdAlta Limited has issued 503,197 fully paid ordinary shares following the exercise of performance rights by employees under the Omnibus Equity Plan. This issuance, conducted without disclosure under specific provisions of the Corporations Act, reflects AdAlta’s compliance with legal obligations and contributes to its strategic equity management, potentially impacting its operational and financial positioning.
More about AdAlta Ltd.
AdAlta Limited is a biotechnology company that focuses on the development of protein-based therapeutics. It is involved in the research and development of novel drugs, utilizing their proprietary i-body technology to address diseases with high unmet medical needs.
YTD Price Performance: -15.00%
Average Trading Volume: 335,613
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$10.73M
Find detailed analytics on 1AD stock on TipRanks’ Stock Analysis page.
